GetTopicDetailResponse(id=7d4f239301f, topicName=二期臨床試驗, introduction=二期臨床試驗, content=null, image=null, comments=0, allHits=821, url=https://h5.medsci.cn/topic?id=23930, type=1, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=48278, tagList=[TagDto(tagId=48278, tagName=二期臨床試驗)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2265064, encodeId=f762226506442, content=<a href='/topic/show?id=4d9e590262a' target=_blank style='color:#2F92EE;'>#無病生存率#</a> <a href='/topic/show?id=7d4f239301f' target=_blank style='color:#2F92EE;'>#二期臨床試驗#</a> <a href='/topic/show?id=79eb40516b' target=_blank style='color:#2F92EE;'>#CAPOX#</a> <a href='/topic/show?id=1f883652ea9' target=_blank style='color:#2F92EE;'>#卡瑞利珠單抗#</a> <a href='/topic/show?id=fe611268949a' target=_blank style='color:#2F92EE;'>#局部晚期直腸癌（LARC）#</a> <a href='/topic/show?id=743411361e66' target=_blank style='color:#2F92EE;'>#總生存率#</a>, objectTitle=BMC Med.：新輔助短程放療后聯(lián)合卡瑞利珠單抗和化療治療局部晚期直腸癌：一項II期研究的3年生存率, objectType=article, longId=875696, objectId=ae6d8e56967c, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240925/1727233846342_8538692.png, objectUrl=/article/show_article.do?id=ae6d8e56967c, replyNumber=0, likeNumber=47, createdTime=2025-05-14, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=ae6d8e56967c, moduleTitle=BMC Med.：新輔助短程放療后聯(lián)合卡瑞利珠單抗和化療治療局部晚期直腸癌：一項II期研究的3年生存率, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=ae6d8e56967c)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2264404, encodeId=2b3822644049d, content=<a href='/topic/show?id=f38743453f7' target=_blank style='color:#2F92EE;'>#多西他賽#</a> <a href='/topic/show?id=231c10011915' target=_blank style='color:#2F92EE;'>#順鉑#</a> <a href='/topic/show?id=3fca4e359e3' target=_blank style='color:#2F92EE;'>#尼妥珠單抗#</a> <a href='/topic/show?id=7d4f239301f' target=_blank style='color:#2F92EE;'>#二期臨床試驗#</a> <a href='/topic/show?id=71d9126e79f2' target=_blank style='color:#2F92EE;'>#復發(fā)或轉移性鼻咽癌(RM-NPC)#</a>, objectTitle=BMC Med：尼妥珠單抗聯(lián)合多西他賽和順鉑作為復發(fā)或轉移性鼻咽癌患者的一線治療：一項多中心、II 期臨床試驗, objectType=article, longId=875432, objectId=7f1c8e5432f6, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240530/1717032442641_92910.png, objectUrl=/article/show_article.do?id=7f1c8e5432f6, replyNumber=0, likeNumber=34, createdTime=2025-05-10, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=7f1c8e5432f6, moduleTitle=BMC Med：尼妥珠單抗聯(lián)合多西他賽和順鉑作為復發(fā)或轉移性鼻咽癌患者的一線治療：一項多中心、II 期臨床試驗, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=7f1c8e5432f6)], followStatus=false, userIsMember=false, type=null, lengthMark=0)]
梅斯話題小助手
2020-05-29
